The term 'antinuclear antibodies' refers. to a diverse group of autoantibodies which are directed against antigens normally (but not exclusively) found in the nucleus. Within the field of paediatric rheumatology antinuclear antibodies are of considerable interest as they are found in most children with juvenile chronic arthritis (JCA) .' The relation between JCA and antinuclear antibodies was first reported over 30 years ago.2 A further 14 years elapsed before the clinical importance of these antibodies in predicting the complication of chronic anterior uveitis was recognised.3 Antinuclear antibodies are an alnost universal finding in the clinical 'syndrome' of early onset pauciarticular JCA with chronic anterior uveitis. It is unlikely, however, that this syndrome has a single cause. Several infectious agents have been implicated in the cause of diseases which are clinically indistinguishable from JCA. 4 5 In addition, there may be considerable overlap between JCA and other rheumatic conditions, such as juvenile psoriatic arthritis6 and systemic lupus erythematosus.7 Probably, chronic childhood arthritis is the 'final common pathway' for many different diseases with different causes, and the term 'JCA' covers a heterogeneous group of diseases. If JCA is due to several causes, and if each cause is associated with specific antinuclear antibodies, children with clinically identical disease might be expected to have antibodies of different specificities. It may be illogical to expect one antinuclear antibody specific for JCA. Even the clinically useful splitting of JCA into onset subtypes (pauciarticular, polyarticular, and systemic) may have little biological relevance, and therefore may not correlate with specific antinuclear antibodies. For convenience, we will continue to refer to 'JCA' in this article, and will use the term interchangeably with juvenile rheumatoid arthritis, while recognising that it is unlikely that either term refers to a single disease entity. 24 25 Although it has been suggested that an IgG antibody against a 45 kD nuclear protein might identify a subgroup of patients without uveitis, 19 no specific anti-nuclear antibodies have been consistently associated with JCA, its clinical subdivisions, or its complications.
Possible future directions for research OVERCOMING DIFFICULTIES WITH CURRENT METHODS
Can antinuclear antibodies which are specific for JCA be found? The answer to this question may be affected by the wide variety of substrates and techniques used to detect these antibodies. Common substrate sources have included mouse kidney and liver; rat liver, kidney, and stomach; rabbit and calf thymus; fresh beef spleen; chicken erythrocytes; and human epithelial cell lines (HEp-2, HeLa, KB), lymphocytic cell lines (K562, WIL2), and leucocytes. The concentration and nature of nuclear components, and therefore the type of antinuclear antibody detected, may vary depending on the substrate source and the extraction techniques used.
Standard techniques for antinuclear antibody detection include indirect immunofluorescence, indirect immunoenzyme assays, Ouchterlony double diffusion, counter current immunoelectrophoresis, immunoblotting, and enzyme linked immunosorbent assays (ELISA). These techniques vary in their ability to detect antibodies depending on the quantity and nature of the immune complexes formed, and the sensitivity of the system used to detect such complexes. Possibly, further characterisation may depend on a substrate or technique that is not in current use.
Immunoblotting is arguably the most suitable initial procedure for characterising antinuclear antibodies as it provides information on the molecular weights of the putative autoantigens,26 and the relevant nuclear antigenautoantibody complex is potentially recoverable from the matrix. In immunoblotting nuclear proteins are separated according to molecular weight by gel electrophoresis, transferred ('blotted') to a solid matrix, and incubated with patients' serum. After washing, any bound human immunoglobulins-that is antinuclear antibodies-are visualised as a 'band' by a labelled antihuman immunoglobulin antibody.27 Unfortunately, immunoblotting is subject to considerable interassay variation, making quality control difficult. Van Dam and colleagues reported that the amount of protein recovered after immunoblotting was strongly influenced by transfer and incubation conditions, and ranged from 10 to 65% of the quantity originally used. 28 The results of immunoblotting are also affected by differences in the sources, method of extraction, and concentration of the nuclear substrate. When immunoblots using nuclear substrates from two different sources, K562 and rabbit thymus extract, were compared, there was an almost complete lack of concordance in the banding patterns of identical JCA serum samples. It is interesting to speculate whether relevant nuclear antigens might be induced by manipulation of the environment and growth conditions of cell lines used for nuclear substrates. Routine assays for antinuclear antibodies such as indirect immunofluorescence of HEp-2 cells, make no attempt to use synchronously cycling cells. During the cell cycle a phase dependent variation in the volume and concentration of the nuclear matrix of the cell occurs. Just before DNA synthesis, for example, the nuclear volume and concentration of non-chromatinic material may increase tenfold (D L Brown, 19th international leucocyte culture conference, BANFF, Alberta, Canada, 1988). Similarly, the nuclear composition is altered by the state of activation of the cell. It is possible that 'phase specific' and 'activity specific' antinuclear antibodies will be found, which might be of relevance to JCA. Indeed, an activated, synchronously cycling cell line was used to delineate antibodies against the proliferating cell nuclear antigen, which is found in about 3% of patients with systemic lupus erythematosus.3'
Other manipulations of the cells might include viral infection, exposure to cytokines, and heat stress. Many viruses have been implicated in the cause of JCA.5 32 Viral infection (adenovirus, cytomegalovirus, Epstein-Barr virus) of the HEp-2 cell line has also been shown to induce dramatic changes in the concentration and cellular distribution of nuclear antigens (La and Sm), perhaps exposing previously 'protected' antigens to the immune system.33 Infection might also induce neoantigens, which could be responsible for selecting the antinuclear antibody repertoire. Antibodies to histone H5 alone have been demonstrated in 10% of patients with JCA.20 Histone H5 is a variant of HI which is unique to non-mammalian species, and is not cross reactive with mammalian protein. On the basis of this finding the authors suggested that 'autoimmunity' in JCA may be initiated by an undiscovered pathogen. Using infected human cell lines as substrate for detection of antinuclear antibodies associated with JCA might yield intriguing results, and similar experiments could be undertaken with high dose cytokines-for example interferon y,33
or stress events such as heat shock.
The role of stress proteins in autoimmunity is currently an area of intense research. Autoantibodies to six stress proteins have been described, including histone H2B. Under pathological conditions, such as rheumatoid arthritis, stress proteins can be expressed on the plasma membrane, where they are accessible to the immune system.34 Some nuclear antigens-for example, ribonucleoproteins-may only become exposed after brief heat shock, though the temperature may have to exceed physiological levels to induce a significant change.35 ' 37 Comparisons between the monoclonal antibodies and native autoantibodies have been performed with 'epitope mapping' techniques. Such studies have shown that the tertiary structure (folded shape) of the native nuclear antigens may be critical to the specificity ofthe autoantibodies generated. 37 It follows that any disruption of this shape, such as the protein denaturation commonly used in immunoblotting techniques, may give results which are misleading or uninterpretable.
Molecular biology techniques could be applied using putative antinuclear antibodies associated with JCA to identify their cognate antigens (the nuclear antigens that they recognise) by screening cDNA expression libraries, with subsequent determination of the amino acid sequence and structure of the antigen. This information may be of use not only to standardise testing for antinuclear antibodies associated with JCA but also to define the function of the 38 autoantigen.
Using antinuclear antibodies to increase our understanding of JCA INVESTIGATING THE GENETIC BASIS OF JCA The genetic basis for JCA is unclear. It is rare for JCA to occur in more than one member of the same family. Although there are several well documented HLA associations with the disease, the relative risk of JCA for any particular HLA allele is low. The prevalence of other autoimmune diseases in the families of patients with JCA is increased,39 and serological evidence of autoimmunity in these families is common.25 In 5/20 families of patients with JCA immunoblot bands of identical molecular weight were shown in both the proband with JCA and one parent.25 No parents had concordant banding patterns. These findings support a genetic predisposition towards autoantibody production, but also suggest that disease development is not simplyadirectconsequenceofsuchautoimmune phenomena.
Previous research has emphasised an association between HLA-DR5 and DRw8, pauciarticular onset JCA, uveitis, and antinuclear antibodies.40 These studies could be extended by analysing the major histocompatibility complex associations of antinuclear antibody expression within families of patients with JCA, and might help clarify the genetic basis of JCA. Evidence from other connective tissue diseases supports the possibility of such an association; for example, HLA-DR5 and anti-DNA-topoisomerase I in scleroderma. 4 Removal of specific 'pathogenic antinuclear antibodies', immune complexes, or cells critical to the formation of such autoantibodies, may be possible with selective plasmapheresis or lymphopheresis techniques. Once the molecular nature of the autoantigen is understood, immunisation against the formation of pathogenic antinuclear antibodies may even be possible using peptide competition techniques.46 47 In conclusion, the study of antinuclear antibodies in patients with JCA is far from complete. At present, tests for these antibodies are clinically useful in helping to highlight those children with JCA who are at particular risk of developing chronic anterior uveitis. Further advances in understanding the specificity of antinuclear antibodies, and the function of their cognate antigens, may come about through improvements in the techniques of antinuclear antibody detection, manipulations of the nuclear substrates used in these techniques, and a greater understanding of the subclassification of JCA. If an association between a specific antinuclear antibody and JCA can be found it will be useful in understanding the basis of the autoimmune process in this disease. 
